DermTech Reports Revenues for H1 2014, Lowers Target for Planned IPO | GenomeWeb

NEW YORK (GenomeWeb) – DermTech reported recently that it recorded $46,000 in revenues for the first six months of the year, up from none a year ago.

The La Jolla, Calif.-based developer of a gene expression-based melanoma test also lowered the targeted amount for its proposed initial public offering to $15 million from $25 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.